Your browser is no longer supported. Please, upgrade your browser.
Settings
CLSN Celsion Corporation daily Stock Chart
CLSN [NASD]
Celsion Corporation
Index- P/E- EPS (ttm)-5.86 Insider Own0.10% Shs Outstand15.00M Perf Week17.92%
Market Cap42.45M Forward P/E- EPS next Y-1.10 Insider Trans- Shs Float14.93M Perf Month41.50%
Income-21.50M PEG- EPS next Q-0.31 Inst Own4.10% Short Float8.00% Perf Quarter108.09%
Sales0.50M P/S84.90 EPS this Y17.50% Inst Trans2.33% Short Ratio0.26 Perf Half Y2.91%
Book/sh1.00 P/B2.83 EPS next Y67.10% ROA-66.80% Target Price9.00 Perf Year-69.60%
Cash/sh0.24 P/C11.79 EPS next 5Y- ROE-286.10% 52W Range1.24 - 9.66 Perf YTD-33.48%
Dividend- P/FCF- EPS past 5Y29.80% ROI-229.70% 52W High-70.70% Beta1.23
Dividend %- Quick Ratio0.50 Sales past 5Y-24.20% Gross Margin- 52W Low128.23% ATR0.30
Employees19 Current Ratio0.50 Sales Q/Q0.00% Oper. Margin- RSI (14)51.63 Volatility11.66% 12.66%
OptionableYes Debt/Eq0.00 EPS Q/Q70.00% Profit Margin- Rel Volume0.27 Prev Close2.64
ShortableYes LT Debt/Eq0.00 EarningsNov 14 BMO Payout- Avg Volume4.53M Price2.83
Recom1.00 SMA2010.92% SMA50-4.20% SMA2004.51% Volume1,217,528 Change7.20%
Oct-04-17Upgrade Maxim Group Hold → Buy $7
Apr-10-17Resumed Rodman & Renshaw Buy $1.50
Nov-10-16Downgrade Maxim Group Buy → Hold
Jul-12-16Resumed H.C. Wainwright Buy $3
Jan-19-16Reiterated Maxim Group Buy $12 → $9
Jul-15-15Initiated Maxim Group Buy $12
Jan-10-14Resumed HC Wainwright Buy $5 → $8
Aug-16-12Reiterated Griffin Securities Buy $10 → $18
Feb-16-12Initiated Brean Murray Buy $7
Oct-26-11Initiated Rodman & Renshaw Mkt Outperform $6
Nov-11-09Initiated Needham Buy $7
Dec-11-17 01:41PM  ETFs with exposure to Celsion Corp. : December 11, 2017 Capital Cube -7.69%
Nov-30-17 01:38PM  ETFs with exposure to Celsion Corp. : November 30, 2017 Capital Cube -7.85%
Nov-29-17 08:04AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-27-17 08:25AM  Recent Analysis Shows Amazon, Oracle, Whiting Petroleum, Mondelez International, Synergy Resources, and Celsion Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire -6.13%
Nov-21-17 08:29AM  Heres Why Celsion Corporation Draws a Vote of Confidence from Oppenheimer SmarterAnalyst +33.64%
Nov-20-17 05:18PM  7 Stock's Moving In Monday's After-Hours Session Benzinga +7.00%
09:30AM  Celsion Corporation (CLSN) Shares Climb on Back of New Findings in Liver Tumours Study SmarterAnalyst
08:00AM  Celsion Announces Publication of the Study of ThermoDox® + Ultrasound, TARDOX Study Protocol in the Journal of Therapeutic Ultrasound GlobeNewswire
Nov-14-17 04:46PM  Edited Transcript of CLSN earnings conference call or presentation 14-Nov-17 4:00pm GMT Thomson Reuters StreetEvents -5.19%
03:29PM  Is It The Right Time To Buy Celsion Corporation (CLSN)? Simply Wall St.
08:10AM  Todays Research Reports on Stocks to Watch: Celsion Corporation and Nektar Therapeutics ACCESSWIRE
08:00AM  Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
07:20AM  Celsion Corporation to Host Earnings Call ACCESSWIRE
Nov-13-17 07:23PM  CORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer GlobeNewswire +6.00%
05:15PM  Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer GlobeNewswire
Nov-07-17 10:00AM  ETFs with exposure to Celsion Corp. : November 7, 2017 Capital Cube
09:00AM  Celsion Corporation to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017 GlobeNewswire
Oct-27-17 09:46AM  Celsion Corporation (CLSN) Spooks Investors with a Share Dilution SmarterAnalyst -19.23%
09:10AM  Celsion Corporation Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock GlobeNewswire
Oct-18-17 08:30AM  Celsion Provides Summary of Research and Development Day Held on October 12, 2017 GlobeNewswire
07:30AM  This Unknown E-Commerce Stock Could Return 300% in 2017 ACCESSWIRE
Oct-17-17 08:30AM  Celsion Provides Summary of Research and Development Day Held on Thursday, October 12, 2017 GlobeNewswire -6.13%
Oct-16-17 08:30AM  Celsion Announces Publication of the HEAT Study Manuscript in the High Impact Journal, Clinical Cancer Research GlobeNewswire
Oct-12-17 11:03AM  Celsion to Host Research and Development (R&D) Day on Thursday, October 12, 2017 GlobeNewswire -11.82%
Oct-10-17 11:11AM  ETFs with exposure to Celsion Corp. : October 10, 2017 Capital Cube +23.66%
Oct-09-17 10:13AM  Cancer Space Last Week Update: Pipeline Expansion in Focus Zacks +11.04%
Oct-04-17 01:45PM  Celsion Corporation Announces Gross Proceeds of $15.6 Million from the Exercise of Existing Common Stock Warrants GlobeNewswire -37.29%
12:24PM  Celsion's Immunotherapy Candidate Impresses, Stock Surges Zacks
09:00AM  Celsion to Host Research and Development Update October 12, 2017 GlobeNewswire
08:35AM  Updated Outlook and Pipeline Review on Celsion Corporation ACCESSWIRE
08:20AM  Today's Research Reports on Stocks to Watch: Celsion Corporation and Cesca Therapeutics ACCESSWIRE
Oct-03-17 09:00AM  Celsion Announces Final Clinical and Translational Research Data from its OVATION Study at the AACR Special Conference on Ovarian Cancer GlobeNewswire +301.32%
Sep-27-17 09:00AM  Celsion Provides Update on ThermoDox® in the Phase III OPTIMA Study of Primary Liver Cancer GlobeNewswire
Sep-18-17 05:35PM  ETFs with exposure to Celsion Corp. : September 18, 2017 Capital Cube +9.09%
Sep-08-17 08:57AM  Stocks Near 52-Week Lows: 4 Attractive Picks Zacks
Aug-31-17 05:46PM  ETFs with exposure to Celsion Corp. : August 31, 2017 Capital Cube
Aug-24-17 10:47AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
09:30AM  Celsion Announces Presentation of OVATION Study Findings at the Upcoming AACR Special Conference GlobeNewswire
Aug-18-17 02:15PM  Edited Transcript of CLSN earnings conference call or presentation 15-Aug-17 3:00pm GMT Thomson Reuters StreetEvents
Aug-15-17 08:00AM  Celsion Corporation Reports Second Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
07:40AM  Investor Network: Celsion Corporation to Host Earnings Call ACCESSWIRE
Aug-08-17 09:00AM  Celsion Corporation to Hold Second Quarter 2017 Financial Results Conference Call on Tuesday, August 15, 2017 GlobeNewswire
Aug-07-17 08:00AM  Data Monitoring Committee Completes Mid-Study Review of Celsions Phase III ThermoDox® OPTIMA Study in Primary Liver Cancer GlobeNewswire -12.26%
Aug-04-17 06:35PM  Celsion Corporation to Delist from the Tel Aviv Stock Exchange GlobeNewswire
Aug-02-17 08:00AM  Celsion Announces Latest Translational Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients GlobeNewswire
Jul-07-17 08:00AM  Today's Research Reports on Stocks to Watch: Valeant Pharmaceuticals and Celsion Corporation Accesswire
Jul-06-17 02:15PM  Celsion Completes Ovarian Cancer Trial Enrollment, Stock Up Zacks -20.66%
09:15AM  Celsion Corporation Announces $5 Million Registered Direct Offering GlobeNewswire
Jul-05-17 10:37AM  This Biotech Stock Is Surging More Than 20% Today TheStreet.com +19.80%
08:00AM  Celsion Announces Completion of OVATION Study and Provides Update on its Immunotherapy Trial in Advanced Stage III and IV Ovarian Cancer GlobeNewswire
Jun-22-17 03:00PM  Celsion Corporation Announces Cancellation of Registered Direct Offering GlobeNewswire +8.68%
Jun-19-17 03:05PM  ETFs with exposure to Celsion Corp. : June 19, 2017 Capital Cube -23.75%
09:15AM  Celsion Corporation Announces $5.4 Million Registered Direct Offering GlobeNewswire
Jun-16-17 07:04AM  Celsion's stock rockets after withdrawing stock offering MarketWatch +56.10%
Jun-14-17 08:00AM  Celsion Corporation Regains Compliance with NASDAQ Listing Requirements GlobeNewswire
Jun-08-17 08:30AM  Celsion Encouraging Ovation Study Results, Pipeline Review and Market Potential Accesswire +7.00%
Jun-05-17 10:15AM  UPDATE: Celsion shares surge 74% on news of positive trial of ovarian cancer treatment MarketWatch +24.06%
09:43AM  Stocks to Watch: Apple, Snap, Herbalife The Wall Street Journal
08:00AM  Celsion Announces Presentation of OVATION Study Findings at the ASCO 2017 Annual Meeting GlobeNewswire
May-30-17 12:21PM  ETFs with exposure to Celsion Corp. : May 30, 2017 Capital Cube -16.40%
May-26-17 04:05PM  Celsion Corporation Announces Stock Consolidation GlobeNewswire
09:39AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 26, 2017 Capital Cube
May-20-17 01:06PM  Edited Transcript of CLSN earnings conference call or presentation 12-May-17 3:00pm GMT Thomson Reuters StreetEvents
May-12-17 09:00AM  Investor Network: Celsion Corporation to Host Earnings Call Accesswire
08:00AM  Celsion Corporation Reports First Quarter 2017 Financial Results and Provides Business Update GlobeNewswire
May-05-17 08:00AM  Celsion Corporation to Hold First Quarter 2017 Financial Results Conference Call on Friday, May 12, 2017 GlobeNewswire
May-04-17 08:00AM  Celsion Updates Clinical Data from the OVATION Study in Newly Diagnosed  Advanced Ovarian Cancer Patients GlobeNewswire
Apr-27-17 03:51PM  ETFs with exposure to Celsion Corp. : April 27, 2017 Capital Cube
Apr-20-17 08:30AM  Celsion Announces Presentation of OVATION Study Findings at the Upcoming ASCO 2017 Annual Meeting GlobeNewswire +6.41%
Apr-17-17 12:50PM  ETFs with exposure to Celsion Corp. : April 17, 2017 Capital Cube
Apr-13-17 08:30AM  Celsion Corporation Reports Preclinical Results of ThermoDox® for the Treatment of Bladder Cancer Published in the International Journal of Hyperthermia GlobeNewswire
Apr-05-17 04:31PM  ETFs with exposure to Celsion Corp. : April 5, 2017 Capital Cube -6.86%
Mar-30-17 01:04PM  CELSION CORP Financials
Mar-29-17 08:46AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017 Capital Cube
Mar-24-17 04:36PM  CELSION CORP Files SEC form 10-K, Annual Report
Mar-16-17 09:03AM  CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
09:00AM  Celsion Corporation Reports Year End 2016 Financial Results and Provides Business Update GlobeNewswire
Mar-15-17 05:40PM  Forget Gilead, Buy These Small-Cap Biotech Stocks Instead Zacks +17.98%
Mar-09-17 09:00AM  Celsion Corporation to Hold Year-End 2016 Financial Results Conference Call on Thursday, March 16, 2017 GlobeNewswire +49.73%
Feb-27-17 08:30AM  Celsion Presents Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium GlobeNewswire +11.14%
Feb-21-17 08:00AM  Celsion Corp. Cancer Medications Insider Buying and Analysis Accesswire -11.00%
Feb-15-17 07:13AM  CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -33.33%
07:00AM  Celsion Corporation Announces $5.0 Million Public Offering GlobeNewswire
Jan-27-17 04:43PM  CELSION CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-19-17 12:40PM  ETFs with exposure to Celsion Corp. : January 19, 2017 Capital Cube
08:00AM  Celsion to Present Two Posters on its GEN-1 IL-12 Gene-Mediated Immunotherapy at the ASCO-SITC Clinical Immuno-Oncology Symposium GlobeNewswire
Jan-18-17 08:00AM  Celsion Corporation Announces Issuance of Two New Patents for ThermoDox® GlobeNewswire -19.41%
Jan-17-17 08:00AM  Celsion Announces Continuing Positive Data from the OVATION Study in Newly Diagnosed Advanced Ovarian Cancer Patients GlobeNewswire +30.77%
Dec-23-16 03:02PM  CELSION CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities,
Dec-22-16 01:12PM  ETFs with exposure to Celsion Corp. : December 22, 2016
Dec-20-16 03:37PM  CELSION CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -25.13%
02:45PM  Celsion Corporation Announces $1.8 Million Registered Direct Offering GlobeNewswire
Dec-16-16 01:30PM  Celsion Corporation Announces Progress with ThermoDox® Development Efforts in China and Asia Pacific GlobeNewswire -7.86%
Dec-01-16 08:00AM  Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer GlobeNewswire
Nov-30-16 08:00AM  Celsion Announces Data Monitoring Committee Unanimously Recommends Continuation of Phase III OPTIMA Study of ThermoDox® for Primary Liver Cancer GlobeNewswire -13.07%
Nov-29-16 08:00AM  Celsion Corporation Announces Presentation of Results from Independent NIH Analysis of ThermoDox® plus Optimized RFA for the Treatment of Primary Liver Cancer at the 2016 RSNA Annual Meeting GlobeNewswire
Nov-16-16 12:58PM  ETFs with exposure to Celsion Corp. : November 16, 2016 +5.52%
Nov-15-16 11:47AM  Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
Nov-10-16 03:10PM  Celsion downgraded by Maxim Group
08:30AM  Celsion Announces Continuing Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Stage III and IV Ovarian Cancer Patients GlobeNewswire
Celsion Corporation, an oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials for recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fritz Frederick J.DirectorJul 07Buy1.906,50012,3506,500Jul 07 04:44 PM
Fritz Frederick J.DirectorJul 07Buy1.886,50012,2209,841Jul 07 04:44 PM
Martinez Alberto R JrDirectorFeb 21Buy0.2335,0008,050180,081Feb 22 09:17 AM
Martinez Alberto R JrDirectorFeb 15Buy0.2245,0009,675145,081Feb 16 11:35 AM